The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).
 
Shahneen Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Genentech (Inst); Merck Sharp and Dohme (Inst); Novartis (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Senhwa Biosciences (Inst)
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis (Inst)
 
Anthony M. Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Merck Serono (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer therapeutic methods
 
Louise Emmett
Consulting or Advisory Role - Clarity Pharmaceuticals; Noxopharm
Speakers' Bureau - Astellas Pharma (Inst); Janssen Oncology; Janssen Oncology; mundipharma
Research Funding - Novartis (Inst); Novartis (Inst); Noxopharm (Inst); Noxopharm (Inst)
 
Megan Crumbaker
Honoraria - Bayer; Merck
Consulting or Advisory Role - Pfizer
Travel, Accommodations, Expenses - MSD Oncology
 
Mathias Bressel
No Relationships to Disclose
 
Rhonda Huynh
No Relationships to Disclose
 
Patricia Diana Banks
No Relationships to Disclose
 
Roslyn Wallace
No Relationships to Disclose
 
Anis Hamid
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; MSD
Travel, Accommodations, Expenses - UroToday
 
Andrisha Jade Inderjeeth
No Relationships to Disclose
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Janssen-Cilag; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; IQvia; Janssen-Cilag; MSD Oncology; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche Molecular Diagnostics; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Ipsen; Janssen-Cilag (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Ramin Alipour
No Relationships to Disclose
 
Grace Kong
Consulting or Advisory Role - Isotopen Technologien
Speakers' Bureau - Ipsen; SAM Nordic
Research Funding - Cyclotek; ITM Isotope Technologies Munich; Pfizer
 
Aravind Ravi Kumar
Research Funding - Varian Medical Systems (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Javad Saghebi
No Relationships to Disclose
 
Scott Williams
Consulting or Advisory Role - Amgen; Janssen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
Timothy J. Akhurst
Employment - intelerad (I)
Stock and Other Ownership Interests - Perkin Elmer (I)
 
Rodney J. Hicks
Stock and Other Ownership Interests - Telix Pharmaceuticals
Consulting or Advisory Role - Revela
 
Michael S Hofman
Consulting or Advisory Role - Janssen; POINT Biopharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Janssen; Mundipharma
Research Funding - Bayer (Inst); Isotopia (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Genzyme; Ipsen; Janssen; Novartis